Geistlich Pharma’s collagen membrane authorized for use in the USA
Wolhusen LU/Schlieren ZH - The Geistlich Nexo-Gide has obtained clearance from the US Food and Drug Administration (FDA). The collagen membrane developed by Geistlich Pharma supports the healing process for tendon and ligament injuries.
The Geistlich Nexo-Gide supports the body’s own healing process for tendon and ligament injuries, Geistlich Pharma writes in a press release. The absorbable, bi-layered collagen membrane developed by the Lucerne-based subsidiary of the Geistlich Group from Schlieren in the canton of Zurich increases the likelihood of successful surgical procedures for patients suffering from severe tendon and ligament injuries.
“Tendon injuries are still a major clinical challenge”, comments Carrie Hartill, Business Unit Director at Geistlich Surgery, in the press release. She explains that tendon and ligament injuries account for nearly half of all the 32 million musculoskeletal injuries recorded in the USA each year. The Geistlich Nexo-Gide is particularly well-suited for use in scenarios where there is no significant loss of tendon tissue.
